Literature DB >> 4074108

The outcome of antidepressant use in the medically ill.

M K Popkin, A L Callies, T B Mackenzie.   

Abstract

To examine the feasibility of using antidepressant medication to treat major depressive syndromes in the hospitalized medically ill, we reviewed a series of psychiatric consultations meeting the following criteria: the consultant diagnosed a major depressive syndrome, treatment with an antidepressant was advised, the consultee initiated the antidepressant, and hospitalization had been prompted by a major medical illness. The final sample of 50 consultations, representing less than 5% of the case reviewed, was assessed by retrospective study of entries in the medical record. Judgments regarding response were thus a function of routine clinical observation and care. Drugs were not randomly assigned; rather, the choices represented ongoing clinical usage patterns. Two major points emerge from the data of the study. First, 32% of the trials were terminated due to side effects judged to be unacceptable by the physicians or consultants. Delirium accounted for half of such side effects; cardiotoxicity, however, was not evident. Second, only 40% of patients with medical illnesses, including malignant neoplasm, insulin-dependent diabetes, and epilepsy, responded to treatment. The trials of antidepressants in medical-surgical inpatients did not achieve the pattern of therapeutic responses routinely characterizing comparable interventions in psychiatric patients with primary affective disorder.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4074108     DOI: 10.1001/archpsyc.1985.01790350034007

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  10 in total

1.  The prediction of recovery using a multivariate model in 1471 depressed inpatients.

Authors:  D W Black; R B Goldstein; A Nasrallah; G Winokur
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1991       Impact factor: 5.270

2.  Major depressive disorder and medical illness: STAR*D outcomes.

Authors:  Prakash Masand; Meera Narasimhan
Journal:  Curr Psychiatry Rep       Date:  2006-06       Impact factor: 5.285

3.  Diagnosis and treatment of depression in the elderly medicare population: predictors, disparities, and trends.

Authors:  Stephen Crystal; Usha Sambamoorthi; James T Walkup; Ayşe Akincigil
Journal:  J Am Geriatr Soc       Date:  2003-12       Impact factor: 5.562

4.  Six-month outcomes for medical patients with major depressive disorders.

Authors:  H C Schulberg; M McClelland; W Gooding
Journal:  J Gen Intern Med       Date:  1987 Sep-Oct       Impact factor: 5.128

Review 5.  Identifying patients at risk for, and treatment of major psychiatric complications of cancer.

Authors:  W Breitbart
Journal:  Support Care Cancer       Date:  1995-01       Impact factor: 3.603

Review 6.  Impact of medical comorbid disease on antidepressant treatment of major depressive disorder.

Authors:  Dan V Iosifescu; Bettina Bankier; Maurizio Fava
Journal:  Curr Psychiatry Rep       Date:  2004-06       Impact factor: 5.285

7.  Validity of the bereavement exclusion criterion for the diagnosis of major depressive episode.

Authors:  Sidney Zisook; Katherine Shear; Kenneth S Kendler
Journal:  World Psychiatry       Date:  2007-06       Impact factor: 49.548

8.  Antidepressant use in elderly medical inpatients: lessons from an attempted clinical trial.

Authors:  H G Koenig; V Goli; F Shelp; H S Kudler; H J Cohen; K G Meador; D G Blazer
Journal:  J Gen Intern Med       Date:  1989 Nov-Dec       Impact factor: 5.128

9.  The IL-6 antagonist tocilizumab is associated with worse depression and related symptoms in the medically ill.

Authors:  Jennifer M Knight; Erin S Costanzo; Suraj Singh; Ziyan Yin; Aniko Szabo; Deepa S Pawar; Cecilia J Hillard; J Douglas Rizzo; Anita D'Souza; Marcelo Pasquini; Christopher L Coe; Michael R Irwin; Charles L Raison; William R Drobyski
Journal:  Transl Psychiatry       Date:  2021-01-18       Impact factor: 6.222

Review 10.  Incomplete remission in depression: role of psychiatric and somatic comorbidity.

Authors:  Christian Otte
Journal:  Dialogues Clin Neurosci       Date:  2008       Impact factor: 5.986

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.